In a landmark decision, the Delhi High Court overturned an injunction against Natco, allowing them to produce a generic version of Novartis’s cancer drug. The Court held that Novartis’s patent on a specific salt form of the drug (ELT-O) lacked novelty due to its coverage in an earlier patent (IN’176).
Read more about Cancerous Battle: Novartis and NATCO clash over EltrombopagTag: Generic drugs
EU Trademark law threatens Indian Generic Export Market
The European Parliament and The Council of The European Union recently passed the Regulation (EU) 2015/2424. The legislation concerns an amendment to the European...
Read more about EU Trademark law threatens Indian Generic Export MarketMylan settles Patent Litigation with Pfizer
Mylan has reached a settlement with Pfizer over patent litigation related to Sildenafil, allowing earlier generic market entry in the US. This agreement is expected to lower drug prices and may signal a trend for further settlements involving Indian pharmaceutical companies.
Read more about Mylan settles Patent Litigation with Pfizer‘Killead’s Patent Application Killed by the Indian Patent Office!
Gilead’s patent for Sofosbuvir was rejected by the Indian Patent Office on grounds of insufficient therapeutic efficacy. This landmark decision enables wider access to affordable generic Hepatitis C treatments in India.
Read more about ‘Killead’s Patent Application Killed by the Indian Patent Office!